{
  "source": "PA-Notification-Lupkynis.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1359-5\nProgram Prior Authorization/Notification\nMedications Lupkynis® (voclosporin)\nP&T Approval Date 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nLupkynis is a calcineurin-inhibitor immunosuppressant indicated in combination with a\nbackground immunosuppressive therapy regimen for the treatment of adult patients with active\nlupus nephritis (LN).\nLimitation of use:\nSafety and efficacy of Lupkynis have not been established in combination with\ncyclophosphamide. Use of Lupkynis is not recommended in this situation.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Lupkynis will be approved based on ALL of the following criteria:\na. Diagnosis of active lupus nephritis\n-AND-\nb. Prescribed in combination with a background immunosuppressive therapy regimen (e.g.,\nmycophenolate mofetil and corticosteroids)\n-AND-\nc. Patient is not receiving Lupkynis in combination with cyclophosphamide\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Lupkynis will be approved based on the following criteria:\na. Documentation of positive clinical response to Lupkynis therapy\n-AND-\nb. Prescribed in combination with a background immunosuppressive therapy regimen (e.g.,\nmycophenolate mofetil and corticosteroids)\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nc. Patient is not receiving Lupkynis in combination with cyclophosphamide\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program.\n• Sup",
    "itial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program.\n• Supply limitations may be in place.\n4. References:\n1. Lupkynis [package insert]. Rockville, MD: Aurinia Pharma U.S., Inc.; April 2024.\nProgram Prior Authorization/Notification - Lupkynis (voclosporin)\nChange Control\n6/2021 New program.\n6/2022 Annual review with no changes to clinical criteria.\n6/2023 Annual review with no changes to clinical criteria. Added state mandate\nfootnote.\n6/2024 Annual review. Updated authorization lengths to 12 months.\n6/2025 Annual review with no changes to clinical criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}